Carregant...
EZH2 Inhibition in Ewing Sarcoma Upregulates G(D2) Expression for Targeting with Gene-Modified T Cells
Chimeric antigen receptor (CAR) engineering of T cells allows one to specifically target tumor cells via cell surface antigens. A candidate target in Ewing sarcoma is the ganglioside G(D2), but heterogeneic expression limits its value. Here we report that pharmacological inhibition of Enhancer of Ze...
Guardat en:
| Publicat a: | Mol Ther |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Gene & Cell Therapy
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6520468/ https://ncbi.nlm.nih.gov/pubmed/30879952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2019.02.014 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|